{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:16:22Z","timestamp":1785312982951,"version":"3.55.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015250","name":"NIHR Bristol Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaip.2023.02.042","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T09:34:54Z","timestamp":1686130494000},"page":"1984-1985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinically accessible biomarkers to assess the modifiable risk of asthma\/wheezing attacks in toddlers"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-6886","authenticated-orcid":false,"given":"Simon","family":"Couillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-0614","authenticated-orcid":false,"given":"Francine M.","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-5973","authenticated-orcid":false,"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.02.042_bib1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaip.2023.01.037","article-title":"Blood eosinophils for prediction of exacerbation in preschool children with recurrent wheezing","volume":"11","author":"Fitzpatrick","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.02.042_bib2","doi-asserted-by":"crossref","first-page":"AB18","DOI":"10.1016\/j.jaci.2021.12.094","article-title":"Efficacy of dupilumab in quadrants of elevated- vs low- type 2 biomarkers in children with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA VOYAGE","volume":"149","author":"Bacharier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.02.042_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2023.02.042_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/23120541.00570-2021","article-title":"Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)","volume":"8","author":"Couillard","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2023.02.042_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.07.024","article-title":"Fractional exhaled nitric oxide measurements are most closely associated with allergic sensitization in school-age children","volume":"124","author":"Jackson","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.02.042_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.02.042_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(23)00004-8","article-title":"Differing effects of mepolizumab across the life course","volume":"11","author":"Bush","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823003136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823003136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:41:49Z","timestamp":1761975709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823003136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2213219823003136"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.02.042","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically accessible biomarkers to assess the modifiable risk of asthma\/wheezing attacks in toddlers","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.01.037","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}